Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Summary
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
Official title: Metformin as an Adjunctive Therapy for the Treatment of Metastatic Colorectal Cancer Patients Undergoing FOLFIRI Plus Target Therapy
Key Details
Gender
All
Age Range
20 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2022-10-31
Completion Date
2025-12-31
Last Updated
2025-02-13
Healthy Volunteers
No
Conditions
Interventions
Metformin Pill
Metformin 500mg TID、FOLFIRI (Leucovorin 200 mg/m2、5-FU 2800 mg/m2、Irinotecan 180 mg/m2) plus target therapy
FOLFIRI plus target therapy only
FOLFIRI (Leucovorin (LV), 200 mg/m2, 2-hour infusion, 5-FU, 2,800 mg/m2, 46-hour infusion, Irinotecan (IRI), 180 mg/m2, 2-hour infusion) plus target therapy
Locations (1)
Chung-Ho Memorial Hospital, Kaohsiung Medical University:
Kaohsiung City, Taiwan